ArticleAsian Pacific journal of cancer prevention : APJCP2026
Circulating microRNAs Expression as Prognosis Biomarker of Cholangiocarcinoma.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholangiocarcinoma (CCA) is a significant problem in Southeast Asia, particularly Thailand. Changes in the expression of microRNAs (miRNA), is one of the mechanisms associated with the pathogenesis and progression of cancer.
objectiveIn the present study, serum miRNA expression from advanced-stage intrahepatic CCA patients was investigated using the high-throughput technique (Nanostring Ncounter© technology).
methodsTwenty-four intrahepatic CCA patients and eight healthy subjects were enrolled in this study. The CCA group was subgrouped according to disease progression into non-metastatic CCA and metastatic CCA.
resultsOf the 803 miRNAs, expression of 239 miRNAs was significantly different among the three groups (p < 0.001). Among them, miR-302d-3p showed the most significant expression (p < 9.02x10-7, FDR: 7.25x10-4), with upregulation in patients with metastatic CCA compared to non-metastic CCA and healthy groups. Fold change analysis revealed that miR-320e expression was the most significantly upregulated across all three groups (p < 0.001). Additionally, the expression levels of miR-223-3p, miR-23a-3p, and miR-302d-3p were significantly increased in patients with both metastatic and non-metastatic CCA compared to healthy controls. Several miRNAs were significantly downregulated, among them, miR-16-5p and miR-451a showed significant downregulation in metastatic and non-metastatic CCA compared with healthy groups.
conclusionsThese findings indicate that a panel of circulating miRNAs may serve as a useful tool for the diagnosis and prognosis of intrahepatic cholangiocarcinoma, warranting further validation in larger cohorts. Additionally, the accuracy of diagnostic tests may be improved by increasing the sample size and including diverse clinical subgroups to enhance the robustness and generalizability of the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.